Spectrum Pharmaceuticals, Inc

Pharma

Henderson, Nevada, United States · Est. 1987

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing oncology and hematology drugs.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Approved1

Phase 21

By Therapeutic Area

top 2

Hematology

150%

Oncology

150%

R&D Momentum

12/100

Pipeline Velocity

0/100

Trial Completion Rate

51/100

Pipeline Concentration

50/100

Pipeline Freshness

48/100

Strategic Signals

↗Active in Hematology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 25, 2026TrialA Randomized, Phase 3 Study of Poziotinib in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring HER2 Exon 20 Mutations (PINNACLE)

Jun 25, 2026TrialA Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Apr 8, 2021TrialA Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

Jan 1, 2021TrialA Study of IGN002 for Refractory NHL

Jun 23, 2020TrialStudy of Poziotinib in Japanese Patients With NSCLC

May 29, 2020TrialStudy of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

Mar 11, 2020TrialOpen-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Dec 23, 2019TrialA Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

4 more events

Jun 25, 2019TrialA Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Oct 5, 2018TrialA Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Jul 13, 2018TrialA Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Oct 13, 2017TrialPhase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

CEOJoe Turgeon

Founded1987

HQHenderson, Nevada, United States

Websitespectrumpharm.com

LinkedInCompany Page

Therapeutic Focus

hematologyoncologyprimary care

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)